p73 protein level is kept extremely low in mammalian cultured cells and its stability may be regulated by not only the ubiquitin/proteasome-dependent proteolysis but also through other unidentified mechanisms. Here, we found for the first time that p73 is physically as well as functionally associated with the U-box-type E3/E4 ubiquitin ligase UFD2a. The immunoprecipitation experiments demonstrated that this interaction is mediated by the COOH-terminal region of p73a containing SAM domain. During the cisplatin-induced apoptosis in SH-SY5Y neuroblastoma cells, p73a accumulated at a protein level, whereas the endogenous UFD2a was significantly reduced in response to cisplatin. Ectopic expression of UFD2a decreased the half-life of p73a in association with a significant inhibition of the p73a-mediated transactivation as well as proapoptotic activity. Downregulation of endogenous UFD2a by antisense strategy resulted in a remarkable accumulation of p73a. Unexpectedly, UFD2a-mediated degradation of p73a was sensitive to the proteasomal inhibitor, however, UFD2a did not affect the ubiquitination levels of p73a. Taken together, our present findings imply that UFD2a might promote the proteasomal turnover of p73 in a ubiquitination-independent manner, and also suggest that UFD2a might play an important role in the regulation of cisplatin-induced apoptosis mediated by p73.
Introduction p73, which is a recently discovered p53 family member (Kaghad et al., 1997) , binds to the p53-responsive elements found within the promoter regions of a variety of p53-target genes, thereby inducing cell cycle arrest and/or apoptosis in certain cancerous cells (for a review, see Melino et al., 2002) . In contrast to p53, p73 gives rise to multiple splice variants with different COOHterminal tails such as p73a and p73b (Melino et al., 2002) . These variants have a different transcriptional and biological property. In fact, the ability of p73b to transactivate the p53-responsive promoters as well as to limit cell growth was stronger than p73a (Jost et al., 1997; De Laurenzi et al., 1998; Ueda et al., 1999) . Deletion of the COOH-terminal end region of p73a restored its transactivation potential, suggesting that the COOH-terminal region of p73a not included in the b form exerts an inhibitory effect on its function (Ozaki et al., 1999; Ueda et al., 1999) . In addition to the COOH-terminal regulatory region, only the a forms of p73 and p63 (another member of p53 family) contain a sterile a motif (SAM) domain, which might mediate protein-protein interactions (Chi et al., 1999; . Although the SAM domain has been found in a variety of cellular proteins closely involved in the developmental regulation (Schultz et al., 1997; , its functional role in the regulation of p73 and p63 remains unclear. Yang et al. (2000) found an NH 2 -terminally truncated form of p73 (DNp73) arising from an alternative promoter usage. DNp73, which lacks the NH 2 -terminal transactivation domain, was expressed predominantly in mouse developing brain and sympathetic neurons and inhibited the p53-dependent neuronal apoptosis by acting as a dominant-negative inhibitor of p53 (Pozniak et al., 2000) . In addition to its function as a p53 antagonist, DNp73 also has a dominant-negative effect on the function of p73 , indicating that the balance between intracellular levels of proapoptotic p73 and tumor-promoting DNp73 might determine the cell fate. We and others have recently shown that p73 directly transactivates DNp73 through the putative p53/p73-target element within the DNp73 promoter region (Grob et al., 2001; Nakagawa et al., 2002; Zaika et al., 2002) , suggesting that there exists a negative feedback regulation of p73 by its own target DNp73.
It has been demonstrated that p73 is stabilized and its proapoptotic activity is enhanced in response to DNA damage such as cisplatin treatment in a pathway depending on nuclear nonreceptor tyrosine kinase c-Abl (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . Ren et al. (2002) described that protein kinase Cd catalytic fragment-mediated phosphorylation of p73 at Ser-289 is strongly associated with the accumulation of p73. Since the steady-state levels of p73 were increased in the presence of the proteasomal inhibitor, p73 stability may be regulated at least in part by the protein degradation process mediated by ubiquitin-proteasome pathway (Balint et al., 1999) . In contrast to p53, MDM2, which mediates the ubiquitination of p53 to trigger its rapid degradation by proteasome, was able to interact with the NH 2 -terminal transactivation domain of p73 to inhibit its function; however, coexpression of MDM2 with p73 resulted in an accumulation of p73 (Zeng et al., 1999) . Thus, p73 stability is regulated by another protein with E3 ubiquitin protein ligase activity. Alternatively, Ohtsuka et al. (2003) found that the proteolytic degradation of p73 is promoted by cyclin G in a ubiquitination-independent manner.
UFD2a, a member of the U-box-type ubiquitin protein ligase family, was initially identified as an E4 ubiquitination factor, which catalyses the elongation of a polyubiquitin chain to allow the targeting of the polyubiquitinated substrate proteins for degradation by proteasome (Koegl et al., 1999; Hatakeyama et al., 2001) . The predicted three-dimensional structure of the U-box resembles that of the RING finger, and UFD2a also acts as an E3 ubiquitin protein ligase (Hatakeyama et al., 2001) . Recently, we have found that human UFD2a gene is mapped to 1p36.2-p36.3, which is a locus for candidate tumor suppressor gene(s) of neuroblastoma and other cancers (Ohira et al., 2000) . However, our mutational analysis suggested that UFD2a is infrequently mutated in neuroblastoma and neuroblastoma-derived cell lines. In yeast, Ufd2 is implicated in cell survival under stress conditions (Koegl et al., 1999) . Upon apoptotic stimuli, UFD2a was cleaved by caspase 6 or granzyme B, and its enzymatic activity was significantly impaired, indicating that UFD2a might play an important role in apoptotic signaling (Mahoney et al., 2002) .
In this report, we showed for the first time that p73a physically interacts with UFD2a in cells. Ectopic expression of UFD2a led to a massive decrease in the levels of p73a in association with a significant reduction of the transactivation as well as proapoptotic function of p73a. Although the UFD2a-mediated proteolytic degradation of p73a was sensitive to the proteasomal inhibitor, UFD2a did not affect the ubiquitination levels of p73a. Our present results strongly indicate that UFD2a participates in the regulation of the steady-state level of p73, thereby modulating the cisplatin-mediated apoptotic response.
Results

Expression of UFD2a
UFD2a is an E3/E4 ubiquitin protein ligase, which contains a regulatory domain and a catalytic U-box at its NH 2 -and COOH-terminal region, respectively ( Figure 1a) . The expression patterns of UFD2a mRNA in various human tissues were examined by Northern blot analysis. Consistent with the previous results (Mahoney et al., 2002) , UFD2a mRNA was expressed at higher levels in human adult heart, placenta and skeletal muscle, whereas adult lung, liver and kidney had low to undetectable levels of UFD2a mRNA on Northern blot (Figure 1b ). In addition, we found that the expression level of UFD2a mRNA was substantially higher in fetal tissues than in their corresponding adult ones. To examine the levels of endogenous UFD2a protein in a variety of mammalian cultured cells, we have generated a polyclonal antibody against the aminoacid sequence in the NH 2 -terminal region of human UFD2a (amino acids 2-149), and analysed the steadystate levels of UFD2a by immunoblotting. Our antibody did not detect the endogenous UFD2a in whole lysates from NB-C201 human neuroblastoma cell line in which þ RNA was hybridized with the radiolabeled human UFD2a cDNA. The B5 kb transcript is shown. Relative RNA loading is shown below by reprobing the membrane with a probe specific for b-actin. a-or g-actin accounts for the fastermigrating band. (c) Immunoblot analysis of UFD2a expression. Whole lysates (50 mg/lane) prepared from the indicated cell lines were separated by a 7.5% SDS-PAGE followed by immunoblotting with the anti-UFD2a antibody (top panel). Equal loading was verified by stripping and reprobing the blot with the anti-actin antibody (bottom panel). (d) Subcellular localization of endogenous UFD2a. The nuclear (N) and cytoplasmic (C) fractions were prepared from U2OS cells. Samples were loaded onto a 7.5% SDS-PAGE and subjected to immunoblotting with the anti-UFD2a (top panel), antiLamin B (middle panel) or anti-Ras (bottom panel) antibody Proteolytic degradation of p73 by UFD2a M Hosoda et al UFD2a gene is homozygously deleted (Ohira et al., 2000) (Figure 1c ). These observations suggest that our antibody is highly specific for UFD2a. Among cell lines, a higher level of expression was observed in SH-SY5Y, SAOS-2, H1299 and Neuro2a cells, and a relatively lower level of expression was detected in U2OS, HEK 293T, H4, A549 and COS7 cells. In accordance with the previous report (Mahoney et al., 2002) , the endogenous UFD2a was detected as a single anti-UFD2a reactive band migrating at B130 kDa, and equal protein loading was confirmed by immunoblotting with an anti-actin antibody.
To determine the subcellular localization of the endogenous UFD2a, we used the biochemical cell fractionation procedure in U2OS cells. Equal amounts of cytoplasmic and nuclear fractions were subjected to immunoblotting with the anti-UFD2a antibody. Ras and Lamin B served as markers for the purity of the cytoplasmic and nuclear fractions, respectively. As described by Hatakeyama et al. (2001) , UFD2a localized to both the cytoplasm and nucleus (Figure 1d ).
Downregulation of UFD2a during the cisplatin-induced apoptosis
The previous reports have shown that yeast Ufd2 is implicated in cell survival under stress conditions including exposure to the heavy metal cadmium and ethanol (Koegl et al., 1999) , and also showed that certain apoptotic stimuli induce the cleavage of human UFD2a by caspase 6 or granzyme B to reduce its enzymatic activity (Mahoney et al., 2002) , raising a possibility that UFD2a might participate in the regulation of proapoptotic proteins. To test this hypothesis, we first investigated the expression levels of UFD2a before and after DNA damage. As described (Nakagawa et al., 2002) , SH-SY5Y cells treated with cisplatin for 24 h underwent apoptosis in a dose-dependent manner as measured by cell survival assays (Figure 2a ), and this apoptotic process was associated with a remarkable increase in proapoptotic p73a and its target p21 WAF1 at a protein level (Figure 2b ). UFD2a was abundantly expressed in untreated SH-SY5Y cells; however, the level of UFD2a was significantly reduced in response to cisplatin treatment. To rule out the possibility that the intracellular level of UFD2a could be regulated at mRNA level, RT-PCR analysis was performed. As shown in Figure 2c , the expression level of UFD2a mRNA remained constant, regardless of cisplatin treatment. These results strongly suggest that the apoptotic signal brought about by cisplatin causes UFD2a downregulation in association with the significant stabilization of p73, and UFD2a might play an important role in the regulation of p73 stability.
Physical interaction of UFD2a with p73
We assessed whether UFD2a could interact with p73 in cells. COS7 cells were transiently transfected with an expression plasmid for FLAG-tagged p73a, and whole lysates were subjected to immunoprecipitation with the anti-UFD2a antibody or with a normal rabbit serum (NRS) followed by immunoblotting with the anti-U FD2a antibody or with an antibody against p73. As shown in Figure 3a , the anti-UFD2a immunoprecipitates contained the endogenous UFD2a as well as FLAG-p73a. In addition, immunoprecipitation of FLAG-p73a resulted in the coprecipitation of the endogenous UFD2a, confirming that UFD2a and p73a are members of the same protein complex. On the other hand, UFD2a did not coimmunoprecipitate with p53 under our experimental conditions (Figure 3b ). Due to the quality of the anti-p73 antibody that we used and/or the extremely low level of p73 in cells, we did not (c) RT-PCR analysis. Total RNA prepared from SH-SY5Y cells exposed to the indicated concentrations of cisplatin for 24 h was subjected to RT-PCR. GAPDH was used as a loading control (bottom panel) detect the complex formation between the endogenous p73a and UFD2a.
SAM domain of p73 is required for interaction with UFD2a
To identify the region(s) of p73 required for the interaction with UFD2a, we expressed a series of p73a deletion mutants as well as p73b in COS7 cells, and examined their abilities to interact with the endogenous UFD2a by coimmunoprecipitation experiments. Their structures are shown in Figure 4a . As reported previously (Ozaki et al., 1999) , HA-p73a (1-427) and HA-p73a (1-548) localized to cell nucleus, whereas HA-p73a (1-247) was detected in both cell nucleus and cytoplasm (data not shown). As shown in Figure 4b and c, all of the p73 proteins, with the exception of p73a (1-548), which retains the SAM domain, were not detected in the anti-UFD2a immunoprecipitates, suggesting that the p73a COOH-terminal region containing SAM domain is required for the interaction with UFD2a.
UFD2a interferes with the steady-state level of p73a but not of p53
To examine a possible effect of UFD2a on p73 stability, U2OS cells were cotransfected with a constant amount of the expression plasmid encoding HA-p73a, HA-p73b or FLAG-p53 together with or without increasing amounts of the FLAG-UFD2a expression plasmid. As shown in Figure 5a , enforced expression of FLAG-UFD2a greatly reduced the levels of HA-p73a in a dose-dependent manner. As expected, FLAGUFD2a had marginal effects on the levels of HA-p73b and FLAG-p53, which did not bind to UFD2a ( Figure  5b and c), suggesting that UFD2a specifically promotes the downregulation of p73a. We next sought to investigate the effect of UFD2a on the endogenous p73a. COS7 cells were transfected with or without increasing amounts of the FLAG-UFD2a expression plasmid, and were subsequently treated with cisplatin or left untreated. Consistent with the previous observations (Tsai and Yuan, 2003) , the endogenous p73a To determine whether UFD2a could affect the halflife of p73, U2OS cells were cotransfected with the expression plasmid for HA-p73a together with or without the FLAG-UFD2a expression plasmid. At 24 h after transfection, cells were treated with cycloheximide (at a final concentration of 20 mg/ml), which inhibits de novo protein synthesis. At the indicated time points following cycloheximide treatment, cells were collected, and whole lysates were analysed for the expression levels of HA-p73a by immunoblotting. As shown in Figure 6a and b, HA-p73a decayed at faster rates in the presence of FLAG-UFD2a than in its absence, whereas the coexpression of FLAG-UFD2a had little effect on the half-life of FLAG-p53. In addition, the half-life of the exogenously expressed HA-p73b was not affected by FLAG-UFD2a (data not shown).
UFD2a-mediated degradation of p73a is regulated in a ubiquitination-independent manner
The results presented on the role of UFD2a in the negative regulation of p73a prompted us to examine whether a ubiquitin-proteasome pathway could be involved in this process. In order to verify this idea, U2OS cells expressing HA-p73a and FLAG-UFD2a were treated with a potent inhibitor of proteasome function, MG-132. As shown in Figure 7a , the UFD2a-mediated reduction of HA-p73a was restored to a level close to the control in the presence of MG-132. Next, we performed the ubiquitination assays. U2OS cells were transiently cotransfected with the expression plasmid for HA-p73a and hexahistidine (His)-tagged ubiquitin together with or without increasing amounts of the FLAG-UFD2a expression plasmid. At 48 h after transfection, cells were exposed to MG-132 for 6 h. Ubiquitinated proteins were isolated by nickel-agarose beads, and then analysed by immunoblotting with the anti-HA antibody. Under our experimental conditions, coexpression of p53 with MDM2 resulted in a remarkable increase in the p53 ubiquitination levels (data not UFD2a decreases the stability of p73a. (a-c) Effect of UFD2a on the expression levels of p73a, p73b and p53. U2OS cells were transiently cotransfected with 0.5 mg of the expression plasmid for HA-p73a (a), HA-p73b (b) or FLAG-p53 (c) together with or without increasing amounts of FLAG-UFD2a expression plasmid (0.5, 1.0 and 1.5 mg). At 48 h after transfection, whole lysates were prepared and analysed by immunoblotting with the indicated antibodies. To control for equal amounts of protein loading, levels of actin were monitored by immunoblotting (bottom panels). (d) UFD2a inhibits the cisplatin-mediated stabilization of endogenous p73a. COS7 cells were transiently transfected with the empty plasmid or with the expression plasmid for FLAG-UFD2a. At 24 h after transfection, cells were treated with 20 mM of cisplatin for 24 h or left untreated, and whole lysates (upper panels) and total RNA (lower panels) were analysed by immunoblotting and RT-PCR, respectively Proteolytic degradation of p73 by UFD2a M Hosoda et al shown). In good agreement with the recent report (Bernassola et al., 2004) , we observed the appearance of the higher molecular weight ubiquitin-conjugated p73a in the presence of His-ubiquitin (Figure 7b) . Unexpectedly, the amounts of the ubiquitinated p73a remained unchanged even in the presence of FLAGUFD2a. As described previously (Hatakeyama et al., 2001) , the COOH-terminal U-box of UFD2a was required for its E3 ubiquitin ligase activity. We have constructed the FLAG-tagged deletion mutant of UFD2a (FLAG-UFD2aD), which lacks the COOHterminal U-box, and examined whether it could reduce the level of p73a. As shown in Figure 7c , FLAGUFD2aD retained an ability to downregulate p73a. Collectively, these results strongly suggest that UFD2a accelerates the proteasomal turnover of p73a in a ubiquitination-independent manner.
UFD2a reduces the p73a-dependent transcriptional activity and proapoptotic function
To further investigate the functional consequences of the interaction between UFD2a and p73a, we tested the effect of FLAG-UFD2a on the p73a-dependent transcriptional activation in p53-deficient human lung carcinoma H1299 cells. As seen in Figure 8a , the enforced expression of HA-p73a resulted in a remarkable induction of the endogenous p21
WAF1
, and coexpression of FLAG-UFD2a with HA-p73a decreased the levels of HA-p73a in association with a significant downregulation of the endogenous p21
. In contrast, FLAG-UFD2a had no obvious effects on the p53-mediated upregulation of the endogenous p21 WAF1 (Figure 8b ).
We next examined a possible effect of UFD2a on the p73a-mediated apoptosis. H1299 cells were transiently cotransfected with a constant amount of the GFP expression plasmid and the expression plasmid for HAp73a or FLAG-p53 together with or without the FLAGUFD2a expression plasmid. At 48 h post-transfection, transfected cells were scored by fluorescence microscopy for the appearance of green fluorescence, and the number of GFP-positive cells with condensed and fragmented nuclei was counted. Overexpression of HA-p73a or p53 led to an increase in the number of apoptotic cells as compared with the control transfection (Figure 8c) . Intriguingly, coexpression of HA-p73a with FLAG-UFD2a decreased the number of apoptotic cells as compared with that resulting from expression of HA-p73a alone. In contrast, FLAG-UFD2a had an undetectable effect on the p53-mediated apoptosis.
Antisense UFD2a enhances the function of p73a
To characterize the effect of the endogenous UFD2a on p73a, we employed antisense strategy to reduce the endogenous UFD2a expression and function. For this purpose, H1299 cells were transiently transfected with an antisense UFD2a expression plasmid (As-UFD2a). At 48 h after transfection, the endogenous levels of UFD2a were analysed by immunoblotting. As shown in Figure 9a , the expression of the antisense UFD2a resulted in a significant decrease in UFD2a protein (left panels). Additionally, coexpression of HA-p73a with the antisense UFD2a led to an increase in the amount of HA-p73a (right panels). H1299 cells were then transiently cotransfected with a constant amount of the expression plasmid for HA-p73a or HA-p73b, together . At 24 h after transfection, cycloheximide was added to the culture medium (20 mg/ml), and whole lysates were prepared at the indicated time points. The levels of HA-p73a and FLAG-p53 were analysed by immunoblotting with the anti-p73 and anti-FLAG antibodies, respectively. Densitometry was used to quantify the amounts of HA-p73a or FLAG-p53, which normalized to actin, and band intensity of HA-p73a or FLAGp53 was calculated against the amount of HA-p73a or FLAG-p53 present at time point 0, which was set at 100%
with the p53/p73-responsive luciferase reporter construct containing p21 WAF1 or Bax promoter in the presence or absence of As-UFD2a. As shown in Figure 9b , the expression of the antisense UFD2a caused a significant enhancement of the ability of p73a to drive transcription from p21 WAF1 or Bax promoter. In contrast, coexpression of the antisense UFD2a with p73b resulted in only a marginal effect on the p73b-mediated transactivation (Figure 9c) . Similar results were also obtained in p53-deficient SAOS-2 cells (data not shown). Consistent with these results, cotransfection of HA-p73a with the antisense UFD2a in H1299 cells induced the endogenous p21 WAF1 compared with that in cells expressing HA-p73a alone (Figure 9d ). These findings collectively demonstrated that the reduction of UFD2a promotes p73a proteasomal turnover in a ubiquitination-independent manner. (a) Effect of proteasomal inhibitor on the UFD2a-mediated degradation of p73a. U2OS cells were transiently cotransfected with 0.5 mg of the HA-p73a expression plasmid together with or without 1.5 mg of the expression plasmid for FLAG-UFD2a. At 24 h after transfection, cells were left untreated or treated with MG-132 (10 mM) for 6 h, and whole lysates were analysed by immunoblotting with the antip73 antibody. Actin was used as a loading control (bottom panel). (b) UFD2a does not increase the ubiquitination levels of p73a. U2OS cells were transiently cotransfected with the indicated combinations of the expression plasmids. At 48 h after transfection, cells were treated with MG-132 for 6 h. Ubiquitinated materials were then isolated by nickel-agarose beads, and analysed by immunoblotting with the anti-HA antibody. (c) Enzymatic activity of UFD2a is not required for the downregulation of p73a. U2OS cells were transiently cotransfected with a constant amount of the expression plasmid for HA-p73a (0.5 mg) together with or without increasing amounts of the FLAG-UFD2aD expression plasmid (0.5, 1.0 and 1.5 mg). At 48 h after transfection, whole lysates were prepared and analysed for HA-p73a. Actin was used as a loading control UFD2a specifically attenuates the p73a-mediated upregulation of p21 WAF1 . p53-deficient H1299 cells were transiently cotransfected with 0.5 mg of the expression plasmid encoding HA-p73a (a) or p53 (b) together with or without 1.5 mg of the FLAG-UFD2a expression plasmid. At 48 h after transfection, whole lysates were analysed by immunoblotting with the indicated antibodies. Actin was used as a loading control (bottom panel). (c) UFD2a inhibits the proapoptotic activity of p73a but not of p53. H1299 cells were transiently cotransfected with the indicated combinations of the expression plasmids. A constant amount of the GFP expression plasmid (200 ng) was included in all the combinations, and the total amount of plasmid DNA was kept constant (2 mg) by including an appropriate amount of empty plasmid. At 48 h post-transfection, transfected cells were identified by the presence of green fluorescence. Cell nucleus was stained with DAPI to reveal nuclear condensation and fragmentation. The number of GFP-positive cells with condensed and fragmented nuclei was scored, and the percentage of apoptotic cells shown in each column represents the mean of three independent experiments the endogenous UFD2a enhances the transactivation ability of p73a.
We next determined a possible effect of antisense UFD2a expression on the p73a-mediated growth suppression. H1299 cells were cotransfected with the expression plasmid for HA-p73a or HA-p73b in the presence or absence of increasing amounts of the antisense UFD2a construct, and cultured in the presence Antisense UFD2a enhances the p73a-mediated transcriptional activity. (a) Antisense UFD2a expression in H1299 cells results in a reduction of endogenous UFD2a. Left panels: H1299 cells were transiently transfected with or without increasing amounts of the antisense UFD2a expression plasmid (As-UFD2a) (0.5, 1.0 and 1.5 mg). Whole lysates were prepared and subjected to immunoblotting with the anti-UFD2a antibody (top panel). Immunoblotting for actin is shown as control for protein loading (bottom panel). Densitometry was used to quantify the amounts of UFD2a, which normalized to actin. Right panels: H1299 cells were transiently cotransfected with 0.5 mg of the HA-p73a expression plasmid along with or without 1.5 mg of As-UFD2a, and whole lysates were analysed by immunoblotting with the indicated antibodies. (b, c) Antisense UFD2a enhances the transcriptional activity of p73a but not of p73b. H1299 cells were transiently cotransfected with 25 ng of the expression plasmid for HA-p73a (b) or HA-p73b (c) together with the p53/p73-responsive luciferase reporter constructs (100 ng) as indicated, and 10 ng of the Renilla luciferase plasmid (pRL-TK) in the presence or absence of the antisense UFD2a expression plasmid (200 ng). Total amounts of plasmid DNA per transfection were kept constant (510 ng) with pcDNA3. At 48 h after transfection, the firefly luciferase activities were determined. The transfection efficiency was standardized against Renilla luciferase. Results shown are representative of three independent experiments. (d) Downregulation of the endogenous UFD2a results in an enhancement of the p73a-dependent induction of p21 WAF1 . Whole lysates prepared from H1299 cells transiently cotransfected with the expression plasmid for HA-p73a (0.5 mg) in the presence or absence of increasing amounts of As-UFD2a (0.5 and 1.5 mg) were analysed by immunoblotting with the indicated antibodies. Actin was used as a loading control (bottom panel)
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M Hosoda et al of G418 (400 mg/ml) for 2 weeks. As shown in Figure  10a and b, coexpression of the antisense UFD2a with HA-p73a resulted in a remarkable reduction in the number of drug-resistant colonies compared with cells transfected with HA-p73a alone, whereas the antisense UFD2a had no significant effect on the growth inhibitory activity of p73b. Taken together, these results indicated that UFD2a destabilizes p73a, thereby reduces its transactivation and proapoptotic activities.
Discussion
UFD2a is a newly identified mammalian homolog of yeast Ufd2 (Koegl et al., 1999) . UFD2a contains a U-box at its COOH-terminus whose predicted threedimensional structure is similar to that of RING finger domain of E3 ubiquitin protein ligases, and in fact it functions as E3 as well as E4 ubiquitin protein ligase, which generates polyubiquitin conjugates from monoubiquitinated substrate proteins (Koegl et al., 1999; Hatakeyama et al., 2001) . Immunohistochemical analysis revealed that UFD2a is expressed predominantly in mouse neuronal tissues, suggesting that UFD2a contributes to the ubiquitination of specific target protein(s) involved in neuronal function (Kaneko et al., 2003) , although its physiological substrate(s) remains to be identified. In the present study, we have demonstrated that UFD2a binds to p73a and this interaction relies on the p73a COOH-terminal region containing SAM domain. Our results also indicated that UFD2a mediates the proteolytic degradation of p73a but not of p53, thereby inhibiting its transactivation as well as proapoptotic activity in cells. Of note, the UFD2a-mediated degradation of p73a was sensitive to the proteasomal inhibitor, however, this degradation process was not associated with the increase in the ubiquitination levels of p73a. Upon cisplatin treatment in SH-SY5Y cells, the endogenous UFD2a was reduced, thereby allowing the accumulation of p73a. Thus, our findings provide an insight into the ubiquitination-independent mechanism for UFD2a-mediated proteolysis of its target proteins such as p73a, although further investigation should be required to clarify the precise molecular mechanism underlying the UFD2a-mediated degradation of p73a. MDM2 promotes the ubiquitination and subsequent degradation of p53 by proteasome, and disruption of the interaction between them is a key event for p53 stabilization (Vousden, 2000) . Since MDM2 is a direct transcriptional target of p53, there exists a unique autoregulatory feedback loop for inhibiting p53 activity. ) for HA-p73a (a) or HA-p73b (b) along with or without increasing amounts of the antisense UFD2a expression plasmid (200, 400 and 800 ng) (As-UFD2a). Total amounts of plasmid DNA per transfection were kept constant (1 mg) with pcDNA3. At 48 h after transfection, cells were split and kept in the medium containing G418 (400 mg/ml), and surviving colonies were counted after 2 weeks Proteolytic degradation of p73 by UFD2a M Hosoda et al
In a sharp contrast to p53, coexpression of MDM2 with p73 resulted in an increase in the amount of p73, although p73 transcriptionally activated the expression of MDM2 and its function such as transcriptional activation, and proapoptotic activity was significantly impaired through the direct interaction of the NH 2 -terminal portion of p73 with MDM2 (Zeng et al., 1999) . Recently, Leng et al. (2003) reported that, like MDM2, a p53-inducible E3 ubiquitin protein ligase Pirh2 regulates the steady-state level of p53 and it participates in a negative autoregulatory feedback loop with p53. Pirh2 bound to p73 (Leng et al., 2003) , but did not promote the p73 degradation (Wu et al., 2004) . On the other hand, Rossi et al. (2005) found that a HECT-type E3 ubiquitin protein ligase Itch ubiquitinates p73 but not p53 and promotes the proteasome-dependent degradation of p73. These findings clearly implicate that p73 stability is regulated through a pathway distinct from that used for p53. Osada et al. (2001) found that the NH 2 -terminally truncated forms of p63 (DNp63) appeared to be much more stable than wild-type p63, suggesting that the NH 2 -terminal transactivation domain of p63 regulates its stability through a pathway that is sensitive to MG-132. Intriguingly, Wu et al. (2004) described that the half-life of DNp73a is extended as compared with that of wild-type p73a, and suggested that the transcriptional activity of p73 is required for its degradation. It is therefore likely that one or more transcriptional targets of p73 might have an ability to target p73 for ubiquitination-mediated degradation by proteasome.
In addition to the ubiquitination-mediated proteasome system, p73 degradation is regulated in a ubiquitination-independent manner. Recently, Ohtsuka et al. (2003) demonstrated that p53-inducible cyclin G, which is also transcriptionally activated by p73, significantly reduced their levels in a ubiquitinationindependent manner, however, the detailed molecular mechanism underlying the cyclin G-mediated degradation of p53 and p73 remains to be defined. Based on our present results, UFD2a mediated the proteasomal turnover of p73a without affecting its ubiquitination levels, and the enzymatic activity of UFD2a was not required for the downregulation of p73a. It is becoming clear that some cellular proteins are subjected to the ubiquitination-independent proteasomal turnover. For example, it has been shown that ornithine decarboxylase (ODC) is degraded by the proteasome independently of ubiquitin modification (Murakami et al., 1992) . In this case, ODC was recruited to the proteasome through the physical interaction with antizyme 1 (AZ1) (Coffino, 2001) . Additionally, Sheaff et al. (2000) found that the direct ubiquitination of p21 WAF1 is not required for its degradation by proteasome. Recently, Jin et al. (2003) described that MDM2 binds to p21 WAF1 and induces its proteasomal turnover without affecting the ubiquitination levels of p21
WAF1
. This might be due to the MDM2-mediated recruitment of p21 WAF1 to the proteasome. Considering that various E3 ubiquitin protein ligases associate with the proteasomal subunits, either directly or through specific adaptor proteins (Xie and Varshavsky, 2002) , it is possible that p73a might be recruited to the proteasome through its binding to UFD2a.
According to previous studies (Jost et al., 1997; De Laurenzi et al., 1998; Ueda et al., 1999) , the ability of p73b to transactivate the p53/p73-responsive promoters as well as to limit cell growth was stronger than p73a. These different functional properties between them might be attributed at least partly to the COOHterminal inhibitory region, which is present in p73a but not in p73b (Ozaki et al., 1999; Ueda et al., 1999) . Recently, Serber et al. (2002) found that the p63a COOH-terminal inhibitory domain binds to its NH 2 -terminal transactivation domain, thereby masking critical residues for transactivation. Based on the structural similarity between the COOH-termini of p73a and p63a, it is possible that the direct intramolecular folding regulates the transactivation function of p73a. In addition to this intramolecular inhibition, the COOHterminal region of p73 might modulate its protein stability. Lee and La Thangue (1999) reported that p73b is considerably more stable than p73a. According to our results, UFD2a bound to p73a but not to p73b and this interaction was mediated by a COOH-terminal extension of p73a containing SAM domain. In contrast to p73a, UFD2a had a negligible effect on the stability and function of p73b. Thus, it is likely that the UFD2a-dependent degradation pathway contributes to the splicing isoform-specific regulation of p73.
The endogenous UFD2a in SH-SY5Y cells was significantly reduced at a protein level in response to cisplatin. During this apoptotic process, p73a accumulated at protein level in association with a remarkable induction of its target p21 WAF1 . It has been shown that the endogenous p73 is stabilized and activated in response to cisplatin treatment in a pathway mediated by nuclear nonreceptor tyrosine kinase c-Abl (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . Alternatively, Ren et al. (2002) described that protein kinase Cd catalytic fragment phosphorylates p73, and increases its stability, suggesting that post-translational modification such as phosphorylation might contribute to the regulation of p73 stability. It is worth noting that the NH 2 -terminal region of UFD2a (amino-acid residues 1-123) is required for its enzymatic activity, and certain apoptotic stimuli, including treatment with staurosporine and ultraviolet irradiation, lead to UFD2a cleavage within the tetrapeptide (120-VDVD-123) by caspase 6 or granzyme B to generate a 110 kDa fragment lacking its NH 2 -terminal region (Mahoney et al., 2002) . Since our polyclonal anti-UFD2a antibody was raised against the NH 2 -terminal polypeptide of UFD2a (amino-acid residues 2-149), it did not recognize the cleaved 110 kDa product. However, we could detect immunoreactive small fragment (B15 kDa) in whole lysates prepared from SH-SY5Y cells exposed to cisplatin (data not shown), indicating that cisplatin treatment causes the cleavage of UFD2a. If this interpretation is correct, the downregulation of UFD2a detected by immunoblotting analysis might be due to the cleavage of UFD2a in response to cisplatin. In preliminary experiments, we have observed that the NH 2 -terminal regulatory region of UFD2a (amino-acid residues 1-149) binds to p73a, whereas the COOHterminal catalytic domain (amino-acid residues 1231-1293) failed to interact with p73a (data not shown). Thus, it is likely that the cisplatin-induced apoptosis might be associated with the cleavage of UFD2a, thereby leading to the dissociation of free active p73a from the UFD2a/p73a complex.
As described previously (Stiewe et al., 2002) , steadystate levels of p73 protein were kept extremely low in various cancer cell lines and normal human diploid fibroblasts. On the other hand, UFD2a was abundantly expressed at mRNA and protein levels in various cancer cell lines (Mahoney et al., 2002) . Given that UFD2a has an ability to promote the degradation of p73a, UFD2a might keep this proapoptotic protein at low levels, thereby preventing cells from apoptotic cell death in response to DNA damage. Thus, it is conceivable that specific inhibition of UFD2a might provide a novel strategy for anticancer treatment.
Materials and methods
Cell cultures and transfection
Human osteosarcoma cell lines (SAOS-2 and U2OS), human embryonic kidney cell line (HEK293T), human neuroglioma cell line (H4), human lung adenocarcinoma cell line (A549), mouse neuroblastoma cell line (Neuro2a) and monkey embryonic kidney cell line (COS7) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin. Human lung carcinoma cell line (H1299) and human neuroblastoma cell lines (NB-C201 and SH-SY5Y) were grown in RPMI 1640 medium containing 10% heatinactivated FBS and antibiotics. Cells were maintained in a humidified atmosphere containing 5% CO 2 at 371C. For transfection, H1299 and U2OS cells were transfected with the indicated expression plasmids using LipofectAMINE Plus reagent (Invitrogen) according to the manufacturer's recommendations. Transient transfection of COS7 cells was performed by FuGENE6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) in accordance with the manufacturer's specifications.
Northern blot analysis
Human UFD2a cDNA was radiolabeled with [a-32 P]dCTP (Amersham Pharmacia Biotech, Piscataway, NJ, USA) by using the random prime labeling kit (Takara Bio Inc., Ohtsu, Japan). A human MTN Blot (Clontech Laboratories, Palo Alto, CA, USA) was hybridized with the radiolabeled probe DNA overnight at 651C in a solution containing 6 Â SSC, 1% N-lauroyl sarcosine, 7.5% dextran sulfate and 200 mg heatdenatured salmon sperm DNA/mI. After hybridization, nonspecific probe was removed by a series of washes. RNA loading was verified by stripping the membrane and reprobing it with a probe specific for b-actin.
RT-PCR
SH-SY5Y cells were exposed to cisplatin (20 mM), and incubated for 0-24 h as indicated. At the indicated time points after the treatment with cisplatin, total RNA was prepared using the RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. The cDNA was generated from each RNA sample (5 mg) using reagents from SuperScript II (Invitrogen), and then used for PCR-based amplification. Specific primers used are as follows: (a) for p73, 5 0 -CTTTGAGGGCCGCATCTG-3 0 (forward primer), 5 0 -GCCCCAGGTTGGGTGTAG-3 0 (reverse primer); (b) for p21
WAF1
, 5 0 -ATGAAATTCACCCCCTTTCC-3 0 (forward primer), 5 0 -CCCTAGGCTGTGCTCACTTC-3 0 (reverse primer); (c) for UFD2a, 5 0 -AAAGCGGAGCCTCAGTGATA-3 0 (forward primer), 5 0 -CTGGATTGGAGCCAGTGTTT-3 0 (reverse primer); (d) for GAPDH, 5 0 -ACCTGACCTGCCGTCTA GAA-3 0 (forward primer), 5 0 -TCCACCACCCTGTTGCTG TA-3 0 (reverse primer).
Antibody production
The rabbit polyclonal antibody specific for human UFD2a was raised against a bacterially expressed GST fusion protein containing the NH 2 -terminal polypeptide of UFD2a (aminoacid residues 2-149). The specificity of the affinity-purified antibody was assayed by immunoblotting analysis.
Cell viability assay
Cell viability was determined by a modified 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide (MTT) assay. In brief, SH-SY5Y cells were seeded in 96-well microtiter plates (5 Â 10 3 cells/well). The next day, the medium was changed and cells were treated with cisplatin for 24 h. For the MTT assay, 10 ml of MTT solution was added to each well for 3 h at 371C. The absorbance readings for each well were carried out at 570 nm using the microplate reader (Model 450, Bio-Rad Laboratories, Hercules, CA, USA).
Immunoblot analysis
Cells were lysed in lysis buffer containing 25 mM Tris-HCI, pH 8.0, 137 mM NaCI, 2.7 mM KCI, 1% Triton X-100, 1 mM PMSF and protease inhibitor mixture (Sigma Chemical Co., St Louis, MO, USA). The protein concentration of the lysates was determined by Bradford protein assay (Bio-Rad Laboratories). Equal amounts of protein were mixed with Laemmli sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.1 M DTT and 0.01% bromophenol blue), run on 8% SDS-PAGE and electroblotted onto PVDF membrane (Immobilon-P, Millipore Corp., Bedford, MA, USA). The membrane was blocked with TBS supplemented with 0.1% Tween 20 and 5% nonfat milk for 1 h at room temperature, and then probed with monoclonal anti-p73 (Ab-4, NeoMarkers Inc., Fremont, CA, USA), monoclonal anti-FLAG (M2, Sigma Chemical Co.), monoclonal anti-HA (12CA5, Roche Molecular Biochemicals), monoclonal anti-p53 (DO-1, Oncogene Research Products, Cambridge, MA, USA), polyclonal anti-p21 WAF1 (H164, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or polyclonal anti-UFD2a antibody for 1 h at room temperature. After three washes, the membrane was incubated with a horseradish peroxidase-conjugated appropriate secondary antibody (Jackson lmmunoResearch Laboratories, West Grove, PA, USA) for 1 h at room temperature. Signals from immunoreactive bands were detected by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech) according to the manufacturer's instructions. Equal loading was checked by reprobing the membrane with polyclonal anti-actin antibody (20-33, Sigma Chemical Co.).
Subcellular fractionation
Cells were washed twice in PBS and lysed in lysis buffer (10 mM Tris-HCI, pH 7.5, and 1 mM EDTA) containing 0.5% NP-40 supplemented with a protease inhibitor mix (Sigma Chemical Co.). The samples were then incubated for 30 min at 41C. Cell fractionation was performed as described previously (Nakamura et al., 1997) . The nuclear and cytoplasmic fractions were subjected to immunoblot analysis using the anti-UFD2a, monoclonal anti-Lamin B (Ab-1, Oncogene Research Products) or monoclonal anti-Ras (RASK-3, Seikagaku Co., Tokyo, Japan) antibody.
Immunoprecipitation analysis
Whole lysates prepared from transfected cells were precleared by incubation with protein G-Sepharose beads (Amersham Pharmacia Biotech) for 1 h at 41C. The supernatant was collected after brief centrifugation, and incubated with the indicated primary antibodies for 2 h at 41C. The immune complexes were precipitated with protein G-Sepharose beads for 1 h at 41C, and the nonspecific bound proteins were removed by washing the beads with the lysis buffer three times at 41C. The immunoprecipitated proteins were eluted by boiling in Laemmli sample buffer, separated on 8% SDS-PAGE and analysed by immunoblotting with anti-p73, anti-HA or anti-UFD2a antibody.
Ubiquitination assay
U2OS cells were transiently cotransfected with the expression plasmid for His-tagged ubiquitin, and HA-p73a together with or without increasing amounts of the expression plasmid for FLAG-UFD2a as indicated. Total amounts of transfected DNA were kept constant by pcDNA3 (Invitrogen) per transfection. At 48 h after transfection, cells were exposed to the proteasomal inhibitor MG-132 (10 mM) for 6 h and then lysed in lysis buffer containing 6 M guanidine-HCI, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 and 10 mM imidazole, pH 8.0. Ubiquitinated proteins were recovered by Ni-NTA resin (Qiagen) and analysed by immunoblotting with the anti-HA antibody.
Luciferase reporter assay H1299 cells were transiently cotransfected with 100 ng of the indicated p53/p73-responsive luciferase reporter plasmid (BAX or p21 WAF1 ), 10 ng of pRL-TK Renilla luciferase cDNA and 25 ng of the indicated expression plasmid (p53 or HA-p73a) in the presence or absence of 200 ng of the antisense UFD2a expression plasmid. The total amounts of DNA were kept constant (510 ng) with pcDNA3. At 48 h after transfection, cells were lysed and luciferase activity was measured by using the dual-luciferase reporter assay system (Promega Corp.) according to the manufacturer's instructions. The normalized luciferase activities represent the firefly luciferase activity corrected for Renilla luciferase as a measure of transfection efficiency.
Protein decay rate analysis U2OS cells were cotransfected with the indicated combinations of the expression plasmids. At 24 h after transfection, cycloheximide (Sigma Chemical Co.) was added to the culture medium at a final concentration of 20 mg/ml and cells were harvested at the indicated time points. Equal amounts of whole lysates (50 mg) were subjected to immunoblot analysis with the anti-p73 antibody.
Apoptosis assay
H1299 cells were transiently cotransfected with 0.2 mg of the GFP expression plasmid and 0.5 mg of the expression plasmid for HA-p73a or p53 together with or without 1.5 mg of the FLAG-UFD2a expression plasmid. At 48 h after transfection, transfected cells were identified by the presence of green fluorescence. Cell nucleus was stained with DAPI to reveal nuclear condensation and fragmentation. The number of GFPpositive cells with apoptotic nuclei was scored.
Colony formation assay
H1299 cells were cotransfected with 200 ng of the expression plasmid encoding HA-p73a or HA-p73b together with or without increasing amounts of the expression plasmid for antisense UFD2a (200, 400 or 800 ng). At 48 h post-transfection, cells were maintained in the culture medium containing G418 (400 mg/ml). After 2 weeks of selection, the plates were stained with Giemsa's solution and numbers of drug-resistant colonies were scored.
